FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

B. Braun Medical Heparin Sodium 25 Recall

Heparin Sodium 25,000 USP units per 250 mL (100 USP units per mL) in 5% Dextrose Inject…

B. Braun Medical Inc · Irvine, CA

Risk level
Class II
Reported by FDA
Jun 19, 2019
Recall ID
D-1343-2019
Check your lot numberHow we source this data

Summary

B. Braun Medical recalled Heparin Sodium 25 starting Jun 13, 2019. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-1343-2019 on Jun 19, 2019. Reason: Subpotent Drug: low out-of-specification results were identified for the drug anti-factor IIa potency which is intended to ensure that the potency of heparin is within the USP specifications. Status: Terminated.

Why it was recalled

Subpotent Drug: low out-of-specification results were identified for the drug anti-factor IIa potency which is intended to ensure that the potency of heparin is within the USP specifications.

Product description

Heparin Sodium 25,000 USP units per 250 mL (100 USP units per mL) in 5% Dextrose Injection, 250 mL EXCEL Container bag, Rx only, B. Braun Medical Inc., Bethlehem, PA 18018-3524 USA, API from SPAIN, NDC 0264-9587-20.

Lot numbers, UPCs & expiration codes

Lot #: J7B259, Exp 31 Aug 2019

Where it was sold

Nationwide in the USA

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1343-2019
Classification
Class II
Status
Terminated
Recall initiated
Jun 13, 2019
FDA report date
Jun 19, 2019
Quantity
40,176 bags
Recall type
Voluntary: Firm initiated
Recalling firm
B. Braun Medical Inc

Original FDA data

Every field from FDA enforcement report D-1343-2019, exactly as published.

Show all FDA fields
City
Irvine
State
CA
Status
Terminated
Country
United States
Event ID
83089
Address
2525 Mcgaw Ave
Code information
Lot #: J7B259, Exp 31 Aug 2019
Postal code
92614-5841
Report date
Jun 19, 2019
Product type
Drugs
Recall number
D-1343-2019
Classification
Class II
Recalling firm
B. Braun Medical Inc
Product quantity
40,176 bags
Termination date
Jul 15, 2022
Reason for recall
Subpotent Drug: low out-of-specification results were identified for the drug anti-factor IIa potency which is intended to ensure that the potency of heparin is within the USP specifications.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Heparin Sodium 25,000 USP units per 250 mL (100 USP units per mL) in 5% Dextrose Injection, 250 mL EXCEL Container bag, Rx only, B. Braun Medical Inc., Bethlehem, PA 18018-3524 USA, API from SPAIN, NDC 0264-9587-20.
Distribution pattern
Nationwide in the USA
Recall initiation date
Jun 13, 2019
Initial firm notification
E-Mail
Center classification date
Jun 13, 2019

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1343-2019, published Jun 19, 2019. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls